Role and relevance of Trkb mutations and expression in non-small cell lung cancer

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 2638-2645

  Harada, Taishi ^a   Yatabe, Yasushi ^b   Takeshita, Masafumi ^c   Koga, Takaomi ^c   Yano, Tokujiro ^d   Wang, Yisong ^a   Giaccone, Giuseppe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 6918; BRAIN DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 3; PROTEIN KINASE INHIBITOR; TROPOMYOSIN RECEPTOR KINASE B; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL CULTURE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENETIC TRANSFORMATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOVEMENT; CELL TRANSFORMATION, NEOPLASTIC; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUTATION; NIH 3T3 CELLS; RECEPTOR, TRKB; SEQUENCE HOMOLOGY, AMINO ACID; TUMOR CELLS, CULTURED;

EID: 79955509427     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3034     Document Type: Article

References (37)

1. Pao W, Chmielecki J. Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-74.
2. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 2003;4:299-309. (Pubitemid 37271375)
3. Beimfohr C, Klugbauer S, Demidchik EP, Lengfelder E, Rabes HM. NTRK1 re-arrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident. Int J Cancer 1999;80: 842-7. (Pubitemid 29108857)
4. Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 1986;319:743-8. (Pubitemid 16145029)
5. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16. (Pubitemid 37328872)
6. Sclabas GM, Fujioka S, Schmidt C, Li Z, Frederick WA, Yang W, et al. Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. Clin Cancer Res 2005;11:440-9. (Pubitemid 40116865)
7. Pearse RN, Swendeman SL, Li Y, Rafii D, Hempstead BL. A neurotrophin axis in myeloma: TrkB and BDNF promote tumor-cell survival. Blood 2005;105:4429-36. (Pubitemid 40720791)
8. Zhang S, Guo D, Luo W, Zhang Q, Zhang Y, Li C, et al. TrkB is highly expressed in NSCLC and mediates BDNF-induced the activation of Pyk2 signaling and the invasion of A549 cells. BMC Cancer 2010;10:43.
9. Desmet CJ, Peeper DS. The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?Cell Mol Life Sci 2006;63:755-9.
10. Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS. Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 2004;430:1034-9.
11. Kupferman ME, Jiffar T, El-Naggar A, Yilmaz T, Zhou G, Xie T, et al. TrkB induces EMT and has a key role in invasion of head and neck squamous cell carcinoma. Oncogene 2010;29:2047-59.
12. Santos FP, Kantarjian HM, Jain N, Manshouri T, Thomas DA, Garcia-Manero G, et al. Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. Blood 2010; 115:1131-6.
13. Giaccone G. Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Future Oncol 2005;1:449-60.
14. Marrari A, Trent JC, George S. Personalized cancer therapy for gastrointestinal stromal tumor: synergizing tumor genotyping with imatinib plasma levels. Curr Opin Oncol 2010;22:336-41.
15. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008;455:1069-75.
16. Marchetti A, Felicioni L, Pelosi G, Del Grammastro M, Fumagalli C, Sciarrotta M, et al. Frequent mutations in the neurotrophic tyrosine receptor kinase gene family in large cell neuroendocrine carcinoma of the lung. Hum Mutat 2008;29:609-16. (Pubitemid 351614584)
17. Voortman J, Lee JH, Killian JK, Suuriniemi M, Wang Y, Lucchi M, et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci U S A 2010;107:13040-5.
18. Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, et al. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2005;2:e313.
19. Marchetti A, Felicioni L, Buttitta F. Assessing EGFR mutations. N Engl J Med 2006;354:526-8;author reply 526-8.
20. Somaiah N, Simon GR. Molecular targeted therapy in non-small cell lung cancer: an overview of available agents. J Thorac Oncol 2009;4: S1046-56.
21. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemiaspecific P210bcr/abl protein. Proc Natl Acad Sci U S A 1988;85: 9312-6. (Pubitemid 19001887)
22. Klein R, Nanduri V, Jing SA, Lamballe F, Tapley P, Bryant S, et al. The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. Cell 1991;66:395-403. (Pubitemid 121001376)
23. Aoyama M, Asai K, Shishikura T, Kawamoto T, Miyachi T, Yokoi T, et al. Human neuroblastomas with unfavorable biologies express high levels of brain-derived neurotrophic factor mRNA and a variety of its variants. Cancer Lett 2001;164:51-60. (Pubitemid 32144989)
24. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM. Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 1994;14:759-67.
25. Bronzetti E, Artico M, Forte F, Pagliarella G, Felici LM, D'Ambrosio A, et al. A possible role of BDNF in prostate cancer detection. Oncol Rep 2008;19:969-74. (Pubitemid 351802667)
26. Li Z, Chang Z, Chiao LJ, Kang Y, Xia Q, Zhu C, et al. TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation. Cancer Res 2009;69:7851-9.
27. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64: 8919-23. (Pubitemid 39665498)
28. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-46. (Pubitemid 40425952)
29. Chang PM, Tzeng CH, Chen PM, Lin JK, Lin TC, Chen WS, et al. ERCC1 codon 118 C->T polymorphism associated with ERCC1 expression and outcome of FOLFOX-4 treatment in Asian patients with metastatic colorectal carcinoma. Cancer Sci 2008.
30. Quintela-Fandino M, Hitt R, Medina PP, Gamarra S, Manso L, Cortes- Funes H, et al. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy. J Clin Oncol 2006;24:4333-9. (Pubitemid 46630792)
31. Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005;11:1534-8. (Pubitemid 40315237)
32. Ricci A, Greco S, Mariotta S, Felici L, Bronzetti E, Cavazzana A, et al. Neurotrophins and neurotrophin receptors in human lung cancer. Am J Respir Cell Mol Biol 2001;25:439-46. (Pubitemid 33037676)
33. Ricci A, Mariotta S, Pompili E, Mancini R, Bronzetti E, De Vitis C, et al. Neurotrophin system activation in pleural effusions. Growth Factors 2010;28:221-31.
34. Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, et al. Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Res 2002;62:6462-6. (Pubitemid 35364107)
35. Jaboin J, Kim CJ, Kaplan DR, Thiele CJ. Brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from chemotherapy- induced apoptosis via phosphatidylinositol 3'-kinase pathway. Cancer Res 2002;62:6756-63. (Pubitemid 35364148)
36. Cancer-genome-atlas-research-network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
37. Bardelli A, Parsons DW, Silliman N, Ptak J, Szabo S, Saha S, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003;300:949. (Pubitemid 36548874)